| Zielpunkt: Universale Zugänglichkeit - Der Weg nach vorn
December 1, 2009 at 12:21 am
|
| NEW YORK--(BUSINESS WIRE)--Im Vorfeld des Welt-AIDS-Tages, der weltweit am 1. Dezember stattfindet, erinnern wir uns daran, dass im Hinblick auf verbesserten Zugang zu Therapien und Prävention ebenso wie im Hinblick auf die Entwicklung neuer Präventionsinstrumente zwar Fortschritte erzielt wurden, die Welt jedoch noch immer nicht am erklärten Ziel angelangt ist, die HIV- und AIDS-Prävention, -Therapie und -Versorgung bis 2010 universell zugänglich zu machen. Nahezu 5,5 M
      
 | Media Files
ViewMedia?mgid=145446&vid=2 (2 KB)
|
| Conquistando Acesso Universal: O Caminho à Frente
December 1, 2009 at 12:00 am
|
| NOVA IORQUE--(BUSINESS WIRE)--Ao nos aproximarmos do Dia Mundial da AIDS, 1 de dezembro, lembramos que embora tenha havido progressos na expansão do acesso ao tratamento e prevenção e que o prgresso foi feito em direção ao desenvolvimento de novas ferramentas proeventivas, o mundo ainda não consegue chegar aos alvos estabelecidos para oferecer acesso à prevenção e tratamento de HIV e AIDS até 2010. Aproximadamente 5,5 milhões de estimadas 9,
 | Media Files
ViewMedia?mgid=145446&vid=2 (2 KB)
|
| Riassunto: La soluzione è raggiungere l'accesso a livello mondiale
December 1, 2009 at 12:00 am
|
| NEW YORK--(BUSINESS WIRE)--Con l'avvicinarsi della Giornata mondiale contro l'AIDS, che si celebrerà a livello globale il giorno 1 dicembre, ci viene ricordato che, nonostante ci sia stato un progresso nell'aumento dell'accesso per la cura e la prevenzione, oltre che per lo sviluppo di nuovi strumenti di prevenzione, il mondo non ha ancora un numero sufficiente di obiettivi stabiliti per fornire un accesso internazionale alla prevenzione, al trattamento e alla cura e per l'HIV e per l'AIDS
 | Media Files
ViewMedia?mgid=145446&vid=2 (2 KB)
|
| Achieving Universal Access: The Way Forward
December 1, 2009 at 12:00 am
|
| NEW YORK--(BUSINESS WIRE)--As we approach World AIDS Day, observed globally December 1, we are reminded that while progress has been made in expanding access to treatment and prevention and that progress has been made toward the development of new prevention tools, the world is still falling short of established targets for providing universal access to HIV and AIDS prevention, treatment and care by 2010. Nearly 5.5 million of the estimated 9.5 million people in need of antiretroviral therapy ar
 | Media Files
ViewMedia?mgid=145446&vid=2 (2 KB)
|
| "Carga positiva," una nueva iniciativa para ayudar a derribar barreras y brindar apoyo a las personas que viven con el VIH/SIDA
November 30, 2009 at 6:45 pm
|
| WASHINGTON, D.C.--(BUSINESS WIRE)--El Fondo Nacional del SIDA (NAF, por sus siglas en inglés) y Bristol-Myers Squibb Company (NYSE: BMY) anunciaron hoy su intención de lanzar un nuevo proyecto denominado “Carga positiva.” Esta iniciativa multianual tiene como objeto la implementación de un plan de ayuda tendiente a derribar las barreras que previenen que las personas infectadas con el VIH reciban el cuidado, tratamiento y apoyo necesarios. El lanzamiento de la iniciati
 |
| ChemGenex to Present Positive Data for Omapro™ From Multiple Clinical Trials at ASH
November 30, 2009 at 5:30 pm
|
| MELBOURNE, Australia & MENLO PARK, Calif.--(BUSINESS WIRE)--ChemGenex Pharmaceuticals Limited (ASX:CXS) announced today that updated clinical data from several of its clinical trials with Omapro™ (omacetaxine mepesuccinate) will be presented at the upcoming 51st American Society of Hematology Annual Meeting in New Orleans, Louisiana. Dr. Jorge Cortes, MD, Professor of Medicine and Deputy Chair in the Department of Leukemia at The University of Texas, MD Anderson Cancer Center will present
 |
| Idaho Technology's FilmArray™ Receives Military Funding for CLIA Waiver Effort
November 30, 2009 at 5:17 pm
|
| SALT LAKE CITY--(BUSINESS WIRE)--The Defense Threat Agency (DTRA), on behalf of the U.S. Air Force Assistant Surgeon General, Modernization Directorate (AF/SGR), has awarded Idaho Technology, Inc. $3.3 million to advance development of the FilmArray™ system and pursue Clinical Laboratory Improvement Amendments (CLIA) waiver from the Food and Drug Administration (FDA). CLIA waiver applies to tests that are simple to perform and interpret, such as rapid Strep tests and pregnancy tests, and c
 | Media Files
ViewMedia?mgid=177922&vid=2 (2 KB)
|
| Litigation Update from the Yaz, Yasmin and Ocella Lawyers at the Roberts Law Firm
November 30, 2009 at 4:58 pm
|
| ST. LOUIS--(BUSINESS WIRE)--The Roberts Law Firm announces that drug defect claims involving the oral contraceptives Yasmin and Yaz have been consolidated and transferred to a federal court in East St. Louis, Ill. On Oct. 1, 2009, the United States Judicial Panel on Multidistrict Litigation entered an order transferring litigation involving claims against the manufacturers of the oral contraceptives Yasmin and Yaz to the U.S. District Court for the Southern District of Illinois (in re: Yasmin an
 |
| PanGenex Signs Licensing Deal to the Enter the $600 Million Spirulla Market
November 30, 2009 at 4:39 pm
|
| CLEARWATER, Fla.--(BUSINESS WIRE)--PanGenex Corporation (Pink Sheets:PGCX), a global nutraceutical and dietary supplement manufacturer and marketer, announced today that it has solidified plans to expand its retail product line with the addition of spirulla. Spirulla, a blue green algae, is an abundant and sustainable natural source of protein, essential fatty acids, vitamins, B12 and minerals that has been used as a dietary health supplement for centuries. Through a licensing agreement with Gre
 |
| Human Genome Sciences Announces Proposed Public Offering of Common Stock
November 30, 2009 at 4:01 pm
|
| ROCKVILLE, Md.--(BUSINESS WIRE)--Human Genome Sciences, Inc. (Nasdaq: HGSI) today announced that it has commenced an underwritten public offering of up to 12,500,000 shares of its common stock. The Company intends to grant the underwriters a 30-day option to purchase up to an additional 1,875,000 shares of the Company’s common stock. The shares will be issued pursuant to a prospectus supplement filed as part of a shelf registration statement previously filed with the Securities and Exchang
 | Media Files
ViewMedia?mgid=195694&vid=2 (2 KB)
|
| Leipzig accueille EuroMedtechMC 2010
November 30, 2009 at 3:59 pm
|
| ZURICH et LEIPZIG, Allemagne--(BUSINESS WIRE)--Le Groupe EBD annonce aujourd'hui que la seconde conférence annuelle de partenariat EuroMedtech™ aura lieu à l'hôtel Westin de Leipzig, en Allemagne, les 1er et 2 juin 2010. EuroMedtech offre aux investisseurs et aux décideurs du secteur des technologies médicales des possibilités de collaboration sans précédent. EuroMedtech attire en effet des sociétés dans tous les domaines des technologies m
 |
| First Commercial Order for Changda International's Thiophene from French Drug Giant
November 30, 2009 at 3:25 pm
|
| WEIFANG, China--(BUSINESS WIRE)--Changda International Holdings (OTCBB: CIHD), the Weifang based specialty chemicals manufacturer has received a first commercial order for it product Thiophene from Sanofi Aventis (NYSE: SNY), the French pharmaceutical multinational. The order was preceded by a rigid due diligence process undertaken by Sanofi on Changda International and its products. “This development emphasizes our high quality standards and ability to compete on an international level an
 |
| Leipzig ist Gastgeber der EuroMedtech™ 2010
November 30, 2009 at 3:21 pm
|
| ZÜRICH und LEIPZIG, Deutschland--(BUSINESS WIRE)--Die zweite jährliche Partnerjahreskonferenz EuroMedtech™ findet vom 1. bis 2. Juni 2010 im Westin Hotel in Leipzig statt. Dies hat die EBD Group heute bekannt gegeben. Die EuroMedtech bietet Entscheidungsträgern und Anlegern aus dem Bereich der Medizintechnik einmalige Möglichkeiten zur Zusammenarbeit. Sie zieht Unternehmen aus allen Bereichen der modernen Medizintechnik an, darunter Technologien für Diagnose, Bildgebung
 |
| VELCADE® (Bortezomib) for Injection to be Featured in Plenary Session at American Society of Hematology
November 30, 2009 at 3:19 pm
|
| CAMBRIDGE, Mass.--(BUSINESS WIRE)--Millennium: The Takeda Oncology Company today announced nearly 200 abstracts have been accepted for presentation at the annual meeting of the American Society of Hematology (ASH) being held December 5–8, 2009 in New Orleans, Louisiana. These abstracts include an oral presentation of data on successful VELCADE utilization in both induction and maintenance in the front-line setting during the distinguished plenary session being held on Sunday, December 6. T
 | Media Files
ViewMedia?mgid=179318&vid=2 (2 KB)
|
| Wedgewood Pharmacy Introduces Tiny Tabs for Megestrol Acetate, Famciclovir
November 30, 2009 at 3:04 pm
|
| SWEDESBORO, N.J.--(BUSINESS WIRE)--In response to requests from veterinarians, Wedgewood Pharmacy is now compounding Tiny Tabs™ in Megestrol Acetate 5mg and Famciclovir 31.25mg. Megestrol Acetate is commonly prescribed by veterinarians for behavioral- and dermatological-related conditions in felines, while Famciclovir is often prescribed for Feline Herpes (FHV-1) infections. Neither Megestrol Acetate nor Famciclovir are commercially available in veterinary health, so veterinarians often cu
 |
| Titan Receives Notice of Allowance for Probuphine® Patent Application in the Treatment of Opiate Addiction
November 30, 2009 at 1:57 pm
|
| SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Titan Pharmaceuticals, Inc (Pink Sheets:TTNP) today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for Titan’s United States patent application directed to the use of Probuphine for the treatment of opiate addiction. The patent application is U.S. Application No. 10/453,377 filed June 2, 2003 titled “Implantable polymeric device for sustained release of buprenorphine”. The newly
 | Media Files
ViewMedia?mgid=206544&vid=2 (2 KB)
|
| Walgreens Announces Executive Promotions
November 30, 2009 at 1:44 pm
|
| DEERFIELD, Ill.--(BUSINESS WIRE)--Walgreens (NYSE: WAG)(NASDAQ: WAG) today announced the following executive promotions: Laura K. Merten, currently Walgreens divisional vice president of health law, has been named divisional vice president of compliance, loss prevention and profit sharing. She replaces Chester G. Young, who is retiring at the end of January after 41 years with the company. Merten, 49, also will replace Young as the company’s chief compliance officer while continuing her ro
 | Media Files
ViewMedia?mgid=75501&vid=2 (2 KB)
|
| Resumen: Leipzig acoge EuroMedtechTM 2010
November 30, 2009 at 1:22 pm
|
| ZURICH & LEIPZIG, Alemania--(BUSINESS WIRE)--EBD Group ha anunciado que el II Congreso anual EuroMedtechTM se celebrará en el hotel The Westin en Leipzig (Alemania), del 1 al 2 de junio, 2010. EuroMedtech ofrece oportunidades sin precedentes para la colaboración entre los directivos del sector de tecnología médica y los inversores. EuroMedtech atrae a empresas de todas las ramas de la industria de la tecnología médica avanzada, incluidas tecnologías de diagn
 |
| Samenvatting: Leipzig ontvangt bijeenkomst EuroMedtech 2010
November 30, 2009 at 1:13 pm
|
| ZURICH & LEIPZIG, Germany--(BUSINESS WIRE)--EBD Group maakt vandaag bekend dat het tweede jaarlijkse partnering congres van EuroMedtech op 1 en 2 juni 2010 zal worden gehouden in het Westin hotel in Leipzig, Duitsland. EuroMedtech biedt ongeëvenaarde kansen voor samenwerking met andere beleidsmakers en beleggers in de medtechwereld. EuroMedtech 2010 brengt wederom beleidsmakers uit alle sectoren van de snel groeiende en sterk innoverende Europese medisch-technologische bedrijfstak bijeen. V
 |
| Riassunto: Lipsia ospiterà l'EuroMedtech™ 2010,
November 30, 2009 at 1:12 pm
|
| ZURIGO & LIPSIA, Germania--(BUSINESS WIRE)--EBD Group ha annunciato oggi che la 2a conferenza annuale per il partnering EuroMedtech™ si terrà presso The Westin Leipzig Hotel a Lipsia, in Germania, l'1 e il 2 giugno 2010. EuroMedtech offre opportunità ineguaguabili di collaborazione tra i responsabili delle decisioni nel campo della tecnologia medica e gli investitori, attirando società operative in tutti i settori della tecnologia medica avanzata, inclusi la diagnostica, l'i
 |
| Introducing anuleaf AD, a Revolutionary New Hemorrhoid Treatment
November 30, 2009 at 12:41 pm
|
| NEW YORK--(BUSINESS WIRE)--Many drug companies desperately do not want revealed to the public that over-the-counter hemorrhoid treatments may worsen problems and cause skin damage. "Steroid creams in particular may cause permanent damage or ulceration of perianal skin," states Laurie Barclay, MD, and Charles Vega, MD in their medical study published in the February 16, 2008 issue of BMJ. Brand-name hemorrhoid treatments have touted the relief effects of their products for years, but they ha
 |
| New Initiative: "Positive Charge" to Help Address Barriers and Provide Support to People Living with HIV/AIDS
November 30, 2009 at 12:30 pm
|
| WASHINGTON--(BUSINESS WIRE)--The National AIDS Fund (NAF) and Bristol-Myers Squibb Company (NYSE: BMY) announced today their intention to launch “Positive Charge,” a new multiyear initiative aimed at helping to break down the barriers that prevent people living with HIV from receiving HIV care, treatment and necessary support. The initiative is slated to launch in January 2010. “Although we have come a long way in the fight against HIV and AIDS, there are more than a milli
 |
| Le 17e Prix de Neuropsychologie Jean-Louis Signoret de la Fondation Ipsen est attribué au Docteur Pierre Maquet pour ses travaux de recherche sur le thème « sommeil et cognition »
November 30, 2009 at 11:30 am
|
| PARIS--(BUSINESS WIRE)--Le 17ème Prix de Neuropsychologie Jean-Louis Signoret de la Fondation Ipsen a été attribué au Docteur Pierre Maquet (Centre de Recherches du Cyclotron, Liège, Belgique). Le jury international1 réuni sous la présidence du Professeur Albert Galaburda (Harvard Medical School, Boston, États-Unis) lui a décerné ce prix pour ses travaux de recherche sur le thème « sommeil et cognition ». D’un monta
 | Media Files
ViewMedia?mgid=156309&vid=2 (2 KB)
|
| The 17Th Jean-Louis Signoret Neuropsychology Prize of La Fondation Ipsen is Awarded to Doctor Pierre Maquet for His Work on the Domain of "Sleep and Cognition"
November 30, 2009 at 11:30 am
|
| PARIS--(BUSINESS WIRE)--The 17th annual Jean-Louis Signoret Neuropsychology Prize has been awarded to Doctor Pierre Maquet (Cyclotron Research Centre, Liege, Belgium) for his work on the domain of “Sleep and cognition” by an international jury1 led by Professor Albert Galaburda (Harvard Medical School, Boston, USA). He received the €20,000 prize on 16 november 2009 at the Journée Jean-Louis Signoret (Paris, France). About the winner Pierre Maquet is Research Director at th
 | Media Files
ViewMedia?mgid=156309&vid=2 (2 KB)
|
| Resumen: PRA International consigue la acreditación más alta en el programa de Medidata para CRO
November 30, 2009 at 11:20 am
|
| NUEVA YORK y RALEIGH, Carolina del Norte--(BUSINESS WIRE)--Medidata Solutions (NASDAQ: MDSO), proveedor líder mundial de soluciones de desarrollo clínico alojadas, ha comunicado que PRA International, organización mundial de investigación clínica (CRO), ha conseguido el estatus Rave Accredited Plus en el programa ASPire to Win® para CROs y otros proveedores de servicios. El nivel más alto del programa, Rave Accredited Plus permite a PRA ofrecer de manera indepe
 | Media Files
ViewMedia?mgid=47691&vid=2 (2 KB)
|
| Samenvatting: PRA International ontvangt hoogste erkenning in het CRO-programma van Medidata
November 30, 2009 at 11:13 am
|
| NEW YORK and RALEIGH, N.C.--(BUSINESS WIRE)--Medidata Solutions (NASDAQ: MDSO), een toonaangevende internationale leverancier van klinische testtoepassingen, maakt vandaag bekend dat PRA International de status Rave Accredited Plus heeft gekregen in het programma getiteld ASPire to Win van Medidata. PRA International is een wereldwijd actieve klinische onderzoeksorganisatie. Met de Rave Accredited Plus, de hoogste rang binnen het programma, kan PRA onafhankelijk zijn klanten het hele pakket aan
 | Media Files
ViewMedia?mgid=47691&vid=2 (2 KB)
|
| Research and Markets: Insomnia or Sleep Disorders Therapy Area Pipeline Report Combines Details on the Top 20 Companies with Products in the Early and Late Stage of Development
November 30, 2009 at 10:45 am
|
| DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/30d3e4/insomnia_or_sleep) has announced the addition of the "Insomnia or Sleep Disorders Therapy Area Pipeline Report" report to their offering. Life Science Analytics, Insomnia or Sleep Disorders Therapy Area Pipeline Report contains detailed information on the insomnia or sleep disorders drug pipeline. This report provides insight into the pipeline status of insomnia or sleep disorders drugs by company an
 |
| Claresa Levetan MD, Co-Founder, CureDM, Inc., Selected for the Class of 2009 Women of Distinction by Philadelphia Business Journal
November 30, 2009 at 9:50 am
|
| WYNNEWOOD, Pa.--(BUSINESS WIRE)--Dr. Claresa Levetan, a co-founder of CureDM, Inc., www.CureDM.com, was named as a 2009 Business Woman of Distinction by the Philadelphia Business Journal and National Association of Women Business Owners. CureDM is a biopharmaceutical company dedicated to developing novel therapeutic approaches to diabetes. Dr. Levetan is recognized for her commitment to science, business and community involvement. “I am extremely proud to have been selected for such a pres
 | Media Files
ViewMedia?mgid=206425&vid=2 (2 KB)
|
| Simulations Plus Reports FY2009 Financial Results
November 30, 2009 at 9:25 am
|
| LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus, Inc. (NASDAQ: SLP), a leading provider of software for pharmaceutical discovery and development, today reported its financial results for its 2009 fiscal year (FY09) ended August 31, 2009. Ms. Momoko Beran, chief financial officer of Simulations Plus, stated: “Fourth quarter fiscal year 2009 (4Q09) consolidated revenues were $1,840,000, an increase of 0.2% or $3,600 from 4Q08. Consolidated revenues for the entire fiscal year 2009 (FY09)
 | Media Files
ViewMedia?mgid=70096&vid=2 (2 KB)
|
| Leipzig to Play Host to EuroMedtech™ 2010
November 30, 2009 at 9:16 am
|
| ZURICH & LEIPZIG, Germany--(BUSINESS WIRE)--EBD Group today announced that the 2nd annual EuroMedtech™ partnering conference will be held at The Westin hotel in Leipzig, Germany, on June 1–2, 2010. EuroMedtech provides unparalleled opportunities for collaboration among medtech decision makers and investors. EuroMedtech attracts companies from all parts of the advanced medical technology industry, including diagnostics, imaging, orthopedics, cardiovascular, biomaterials and eHealth te
 |
| Cannabis Science Appoints Three Distinguished Physicians As New Members To Its Scientific Advisory Board: Dr. Ben Johnson, Dr. Alan Shackleford, and Dr. William Courtney
November 30, 2009 at 9:09 am
|
| COLORADO SPRINGS, Colo.--(BUSINESS WIRE)--Cannabis Science Inc. (NASD OTCBB: CBIS) an emerging pharmaceutical cannabis company, is honored to announce that Dr. Ben Johnson, Dr. Allan Shackleford and Dr. William Courtney have accepted its request to become members of its recently formed Scientific Advisory Board. The formation of the Scientific Advisory Board was announced on August 6th with the appointment of Dr. Mitch Earlywine Ph. D. as its first member, and the appointment Dr. Ritchard L. Fis
 |
| Tongjitang to Hold 2009 Annual General Meeting on December 23, 2009
November 30, 2009 at 9:00 am
|
| SHENZHEN, China--(BUSINESS WIRE)--Tongjitang Chinese Medicines Company (the “Company” or “Tongjitang”) (NYSE: TCM), a leading specialty pharmaceutical company focusing on the development, manufacturing, marketing and selling of modernized traditional Chinese medicine in China, today announced that it will hold its annual general meeting of shareholders for the fiscal year ended December 31, 2009 at the Company’s executive office on 5th Floor, Block B, Nanshan Medica
 |
| Sunshine Biopharma, Inc. Announces New Trading Symbol
November 30, 2009 at 9:00 am
|
| MONTREAL--(BUSINESS WIRE)--Sunshine Biopharma, Inc., (OTCBB: MWBN) today announced that the trading symbol for its common stock has changed to “SBFM”effective immediately. Sunshine Biopharma is a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer. The Company’s lead compound, Difluoro-Etoposide™, is a multi-purpose anti-tumor compound that is expected to enter Phase I clinical trials in C
 |
| Inovio Partner Announces Completion of Phase I DNA Vaccine Study
November 30, 2009 at 9:00 am
|
| SAN DIEGO--(BUSINESS WIRE)--Inovio Biomedical Corporation (NYSE Amex:INO), a leader in DNA vaccine design, development and delivery, announced today that its partner Tripep AB of Sweden has completed its phase I clinical study of its ChronVac-C hepatitis C virus DNA vaccine delivered using Inovio’s electroporation technology. The study established the safety and tolerability of this therapy, with vaccine-induced immune responses and transient effects on the serum levels of hepatitis C viru
 | Media Files
ViewMedia?mgid=42777&vid=2 (2 KB)
|
| Depomed Files Patent Infringement Lawsuit Against Lupin Limited
November 30, 2009 at 9:00 am
|
| MENLO PARK, Calif.--(BUSINESS WIRE)--Depomed, Inc. (Nasdaq:DEPO) today announced that it has filed a lawsuit in the United States District Court for the Northern District of California against Lupin Limited and its wholly-owned subsidiary, Lupin Pharmaceuticals, Inc., for infringement of the patents listed in the Orange Book for GLUMETZA® (metformin hydrochloride extended release tablets). The lawsuit is in response to an Abbreviated New Drug Application (ANDA) filed by Lupin with the U.S.
 |
| TargetRx Introduces New Research Capability to Increase Effectiveness of Co-Pay Card Initiatives
November 30, 2009 at 9:00 am
|
| HORSHAM, Pa.--(BUSINESS WIRE)--Companies marketing branded pharmaceuticals are facing an increasing need to make products more accessible and affordable for patients. Furthermore, the rise of competition among branded drugs has led many pharmaceutical companies to focus less on DTC spending and more on increased investment in co-pay card programs in order to make these treatments more cost-effective for patients. In response to this market demand, TargetRx today announced a new offering that ena
 | Media Files
ViewMedia?mgid=43986&vid=2 (2 KB)
|
| Consumers Pay Little or No Attention to Drug Company's Advertised Risk Disclosures, Latest Under the Skin Study from ORC Guideline Finds
November 30, 2009 at 9:00 am
|
| NEW YORK--(BUSINESS WIRE)--When it comes to risk disclosures made by drug companies in print and television ads, many consumers are not paying attention, according to a recent study by ORC Guideline (an infoGROUP company) (NASDAQ: IUSA). The latest study in the company’s Under the Skin series found that 41% of US consumers pay little or no attention to risk information presented by pharmaceutical companies in their TV commercials, and only half (50%) pay attention to such disclosures in pr
 | Media Files
ViewMedia?mgid=138091&vid=2 (2 KB)
|
| Emisphere Technologies Announces Extension of Maturity Date for Novartis Convertible Promissory Note
November 30, 2009 at 8:45 am
|
| CEDAR KNOLLS, N.J.--(BUSINESS WIRE)--Emisphere Technologies, Inc. (OTC BB: EMIS), a biopharmaceutical company that focuses on a unique and improved delivery of pharmaceutical compounds and nutritional supplements using its Eligen® Technology, today announced that Novartis Pharma AG has agreed to extend the maturity date of Emisphere’s Convertible Promissory Note (the “Note”) to February 26, 2010. The $10 million original principal amount Note, plus interest accrued to date
 |
| PRAインターナショナルがメディデータ・ソリューションズのCRO向けプログラムで 最高レベルの認定を取得
November 30, 2009 at 8:30 am
|
| NEW YORK & RALEIGH, N.C.--(BUSINESS WIRE)--ホスト型臨床開発ソリューションのリーディング・グローバル・プロバイダである メディデータ・ソリューションズ（NASDAQ: MDSO）は
 | Media Files
ViewMedia?mgid=47691&vid=2 (2 KB)
|
| Riassunto: PRA International raggiunge il riconoscimento più elevato nel programma CRO di Medidata
November 30, 2009 at 8:30 am
|
| NEW YORK e RALEIGH, North Carolina--(BUSINESS WIRE)--Medidata Solutions (NASDAQ: MDSO), uno dei più importanti fornitori globali di soluzioni ospitate di sviluppo clinico, ha annunciato oggi che PRA International, un'organizzazione di ricerche cliniche (CRO) globale, ha raggiunto la categoria Rave Accredited Plus nel programma ASPire to Win® per CRO e altri fornitori di servizi. Essendo l'ordine massimo raggiungibile nel programma, la categoria Rave Accredited Plus consente a PRA Inter
 | Media Files
ViewMedia?mgid=47691&vid=2 (2 KB)
|
| PRA International obtient la plus haute accréditation dans le programme de Medidata pour les CRO
November 30, 2009 at 8:30 am
|
| NEW YORK et RALEIGH, Caroline du Nord--(BUSINESS WIRE)--Medidata Solutions (NASDAQ: MDSO), un fournisseur mondial de premier plan de solutions hébergées de développement clinique, a annoncé aujourd'hui que PRA International, un organisme de recherche clinique (CRO) mondial, avait obtenu l’accréditation Rave Accredited Plus dans le programme ASPire to Win® pour les CRO et les autres fournisseurs de services. Le niveau le plus élevé du programme, Rave
 | Media Files
ViewMedia?mgid=47691&vid=2 (2 KB)
|
| PRA International erhält höchste Akkreditierung im Rahmen des CRO-Programms von Medidata
November 30, 2009 at 8:30 am
|
| NEW YORK und RALEIGH, North Carolina--(BUSINESS WIRE)--Medidata Solutions (NASDAQ: MDSO), ein führender, weltweit tätiger Anbieter von gehosteten Lösungen für die klinische Entwicklung, teilte heute mit, dass PRA International, ein globales Auftragsforschungsinstitut (CRO), den Status Rave Accredited Plus im Rahmen des ASPire-to-Win®-Programms für CROs und andere Dienstleistungsanbieter erhalten hat. Rave Accredited Plus, die höchste Stufe des Programms, erm
 | Media Files
ViewMedia?mgid=47691&vid=2 (2 KB)
|
| PRA International Achieves Highest Accreditation in Medidata CRO Program
November 30, 2009 at 8:30 am
|
| NEW YORK and RALEIGH, N.C.--(BUSINESS WIRE)--Medidata Solutions (NASDAQ: MDSO), a leading global provider of hosted clinical development solutions, today announced that PRA International, a global clinical research organization (CRO), has achieved Rave Accredited Plus status in the ASPire to Win® program for CROs and other service providers. The highest achievable tier in the program, Rave Accredited Plus enables PRA to independently offer its customers a full suite of services around the M
 | Media Files
ViewMedia?mgid=47691&vid=2 (2 KB)
|
| Research and Markets: Pharmaceutical Industry in Czech Republic
November 30, 2009 at 8:23 am
|
| DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/ae61fd/pharmaceutical_ind) has announced the addition of the "Pharmaceutical Industry in Czech Republic" report to their offering. The birth origins of the Pharmaceutical Industry can be traced back to more humble antecedents than just chemistry labs. The earliest incidents of recognition of the antiseptic properties of the dyestuffs is around the late 19th century. The invention of penicillin can yet be re
 |
| Research and Markets: Pharmaceutical Industry in South Korea
November 30, 2009 at 8:17 am
|
| DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/0b4c07/pharmaceutical_ind) has announced the addition of the "Pharmaceutical Industry in South Korea" report to their offering. The birth origins of the Pharmaceutical Industry can be traced back to more humble antecedents than just chemistry labs. The earliest incidents of recognition of the antiseptic properties of the dyestuffs is around the late 19th century. The invention of penicillin can yet be recog
 |
| Allos Therapeutics Announces Issuance of U.S. Patent for FOLOTYN
November 30, 2009 at 8:00 am
|
| WESTMINSTER, Colo.--(BUSINESS WIRE)--Allos Therapeutics, Inc. (Nasdaq:ALTH) today announced that the United States Patent and Trademark Office has issued a patent for the use of FOLOTYN™ (pralatrexate injection) for the treatment of T-cell lymphoma. U.S. Patent No. 7,622,470 was issued to Memorial-Sloan Kettering Cancer Center, SRI International and Southern Research Institute, and expires on November 24, 2025. Allos holds an exclusive worldwide license from these institutions to develop a
 | Media Files
ViewMedia?mgid=195346&vid=2 (2 KB)
|
| Millennium Laboratories Announces National Pain Management Services Agreement with Three Rivers Provider Network
November 30, 2009 at 8:00 am
|
| SAN DIEGO, Calif.--(BUSINESS WIRE)--Millennium Laboratories, a leading provider of therapeutic drug monitoring and education to physicians and staff treating chronic pain patients, announced today an agreement with Three Rivers Provider Network (TRPN), the largest and fastest growing proprietary Preferred Provider Organization (PPO) network in the United States. The agreement names Millennium Laboratories as a participating provider of pain management services for the TRPN network that is compri
 |
| Xencor Licenses Antibody Optimization Technology
November 30, 2009 at 8:00 am
|
| MONROVIA, Calif.--(BUSINESS WIRE)--Xencor, Inc., a company using Fc engineering for the discovery and development of next-generation and biosuperior antibodies, announced today that it has licensed its XmAb® and Xtend™ technology platforms to Centocor Research & Development, Inc. (“Centocor”) for the optimization of Centocor’s antibody drug candidates. The license follows a 2009 license agreement that gave Centocor access to Xencor’s proprietary Immunofilte
 | Media Files
ViewMedia?mgid=102409&vid=2 (2 KB)
|
| ReSearch Pharmaceutical Services, Inc. (RPS) Establishes Global Platform to Capitalize on Outsourced Clinical Trials
November 30, 2009 at 8:00 am
|
| FORT WASHINGTON, Pa.--(BUSINESS WIRE)--ReSearch Pharmaceutical Services, Inc. (RPS), a next generation contract research organization (CRO) and provider of integrated clinical development outsourcing solutions, today announced the completion of its global platform to provide advanced integrated CRO services across four continents. RPS has positioned itself to capitalize on the growth of global clinical trials. PharmaVoice reported that up to 65% of FDA-regulated clinical trials in the next three
 |
| Research and Markets: Mapping the Healthcare Landscape: Bringing Pharmaceuticals into Focus
November 30, 2009 at 7:59 am
|
| DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/3faa7a/mapping_the_health) has announced the addition of the "Mapping the Healthcare Landscape: Bringing Pharmaceuticals into Focus" report to their offering. Courtesy of the patent cliff, the pharmaceutical industry is set for a dramatic slow down in revenue growth from 2011. Industry players are therefore looking to implement strategies which will cushion them against the anticipated revenue short-fall, w
 | | | 
|
没有评论:
发表评论